Management of Peyronie's Disease after Collagenase (Xiaflex:®)

Author(s): Amjad Alwaal, Ahmed Aly Hussein, Uwais B. Zaid, Tom F. Lue

Journal Name: Current Drug Targets

Volume 16 , Issue 5 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Although the prevalence of Peyronie’s disease (PD) is reported to be 3-9% in men, the true prevalence is likely higher due to under-reporting. Many treatment modalities have been described for PD with varying degrees of success. In this article, we review and summarize the current literature pertaining to all pharmacotherapies (oral, intralesional, iontophoresis, and topical) and minimally invasive treatments available for PD (vacuum, traction device, shock wave therapy, and radiation treatment). Additionally, we discuss emerging therapies for PD that are still in pre-clinical development, including stem cell therapy.

Keywords: Pharmacotherapy, Peyronie’s disease, shock wave therapy, stem cell therapy, collagenase.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 04 May, 2015
Page: [484 - 494]
Pages: 11
DOI: 10.2174/1389450115666141114163128
Price: $65

Article Metrics

PDF: 40